Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00519142 · ClinicalTrials.gov registry record · Phase 3
Mitiglinide in Combination With Metformin vs. Metformin Alone in Patients With Type 2 Diabetes Mellitus
A Phase 3 study of Diabetes Mellitus, Type 2, sponsored by Elixir Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 367
- Enrollment target
- 20
- Study locations
NCT00519142: Completed Phase 3 study of Diabetes Mellitus, Type 2, sponsored by Elixir Pharmaceuticals.
NCT00519142 is a Phase 3 study of Diabetes Mellitus, Type 2 that has completed, run by Elixir Pharmaceuticals. The registered enrollment target is 367 participants, below the 4,484-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (92% lower). The trial reports 20 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00519142, a Phase 3 study of Diabetes Mellitus, Type 2, has completed, sponsored by Elixir Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 367 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objective of this study is to demonstrate whether mitiglinide administered in combination with metformin is more effective than metformin alone in patients with Type 2 diabetes mellitus (T2DM) whose blood sugar is not well controlled taking metformin alone. This is a 24 week study which measures improvement in blood sugar after of treatment.
Conditions Studied
Interventions
- DRUG placebo for mitiglinide
- DRUG mitiglinide
Study Locations (20)
California
- Elixir Study Site - Greenbrae
- Elixir Study Site - La Jolla
- Elixir Study Site - Los Angeles
- Elixir Study Site - Los Gatos
- Elixir Study Site(s) - Oakland Area
- Elixir Study Site - Orange
- Elixir Study Site - West Hills
- Elixir Study Site - Westlake Village
Florida
- Elixir Study Site - Chiefland
- Elixir Study Site - Coral Gables
- Elixir Study Site - Kissimmee
- Elixir Study Site(s) - Miami
- Elixir Study Site - Saint Cloud
- Elixir Study Site - Winter Park
Georgia
- Elixir Study Site - Atlanta
- Elixir Study Site - Austell
- Elixir Study Site - Perry
Arizona
- Elixir Study Site - Glendale
Colorado
- Elixir Study Site - Pueblo
District of Columbia
- Elixir Study Site(s) - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 367 participants |
| Start Date | 2007-08 |
| Est. Completion | 2008-10 |
| Phase | Phase 3 |
What the finished NCT00519142 record still lists
NCT00519142 is an interventional study that assigns participants to a tested intervention. The registered 367 participants enrollment target is mid-sized for trials with a published cap, below the 4,484-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (92% lower).
The record links to 1 condition, with Diabetes Mellitus, Type 2 appearing as the primary indexed condition, and to 2 interventions - of which placebo for mitiglinide is the first listed.
NCT00519142 names 20 study sites across 6 states, led by California, Florida, Georgia.
Frequently Asked Questions
What is clinical trial NCT00519142 about?
NCT00519142 is a clinical study titled "Mitiglinide in Combination With Metformin vs. Metformin Alone in Patients With Type 2 Diabetes Mellitus". The primary objective of this study is to demonstrate whether mitiglinide administered in combination with metformin is more effective than metformin alone in patients with Type 2 diabetes mellitus (T2DM) whose blood sugar is not well controlled taking metformin alone. This is a 24 week study which ...
What is the current status of trial NCT00519142?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 367 participants. The study started on 2007-08. Estimated completion is 2008-10.
What conditions does trial NCT00519142 study?
This clinical trial studies the following conditions: Diabetes Mellitus, Type 2.
What interventions are being tested in trial NCT00519142?
The interventions under investigation include: placebo for mitiglinide (DRUG), mitiglinide (DRUG).
Who is sponsoring clinical trial NCT00519142?
This trial is sponsored by Elixir Pharmaceuticals, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00519142 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes Mellitus, Type 2
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00519142's enrollment target sits among peer trials
367 99th of 348 higher than 250 of 348 other Diabetes Mellitus, Type 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diabetes Mellitus, Type 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
RECRUITING · Phase 3
-
Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)
ACTIVE NOT RECRUITING · Phase 3
-
A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes
ACTIVE NOT RECRUITING · Phase 3
-
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight
ACTIVE NOT RECRUITING · Phase 3
-
A Research Study to Find Out How Semaglutide Works in the Kidneys Compared to Placebo, in People With Type 2 Diabetes and Chronic Kidney Disease (the REMODEL Trial)
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04675476 · 368 participants · NA
A Patient and Provider Intervention to Address Health Disparities in Lung Cancer Screening
- NCT05215353 · 368 participants · Phase 4
A Study Comparing Music Therapy and Cognitive Behavioral Therapy for Anxiety in Cancer Survivors
- NCT06182397 · 368 participants · NA
Sirolimus Coated BALloon Versus Standard Balloon Angioplasty in The Treatment of Below The Knee Arterial Disease
- NCT06629610 · 368 participants · NA
Diet and Active Lifestyle - Yuuyaraq (The Yup'ik Way of Life)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia